Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Medtronic
Harvard Business School
Merck
Mallinckrodt

Last Updated: August 10, 2022

CLINICAL TRIALS PROFILE FOR MITOSOL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Mitosol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01004978 ↗ Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Active, not recruiting National Cancer Institute (NCI) Phase 3 2009-10-28 This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoembolization kills tumor cells by carrying drugs directly into blood vessels near the tumor and then blocking the blood flow to allow a higher concentration of the drug to reach the tumor for a longer period of time. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemoembolization together with sorafenib tosylate is more effective than chemoembolization alone in treating patients with liver cancer.
NCT01017640 ↗ Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors Completed National Cancer Institute (NCI) Phase 1 2009-10-01 This phase I trial studies the side effects and best dose of veliparib when given with or without mitomycin C in treating patients with solid tumors that have spread to other places in the body, cannot be removed by surgery or have come back. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with mitomycin C may kill more tumor cells.
NCT02369458 ↗ Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies Recruiting Washington University School of Medicine Phase 2 2015-04-14 No agent is known to have efficacy in patients with incurable HNSCC that progressed with prior platin, 5-FU, cetuximab and taxane. Herein lies the unmet need to be addressed by this trial. Based on the preclinical and clinical data presented, the investigators propose that mitomycin C will have anti-tumor activity in these patients.
NCT02805257 ↗ Ahmed Glaucoma Valve Surgery With Mitomycin-C Completed Asociación para Evitar la Ceguera en México Phase 2 2016-06-01 This study will determine the effectiveness of Mitomycin-C use in the glaucoma surgery Ahmed valve implantation. Approximately 100 patients will be enrolled, with half receiving the Mitomycin-C treatment and the other half receiving placebo treatment.
NCT02805257 ↗ Ahmed Glaucoma Valve Surgery With Mitomycin-C Completed Bascom Palmer Eye Institute Phase 2 2016-06-01 This study will determine the effectiveness of Mitomycin-C use in the glaucoma surgery Ahmed valve implantation. Approximately 100 patients will be enrolled, with half receiving the Mitomycin-C treatment and the other half receiving placebo treatment.
NCT02805257 ↗ Ahmed Glaucoma Valve Surgery With Mitomycin-C Completed Hospital Central Militar Phase 2 2016-06-01 This study will determine the effectiveness of Mitomycin-C use in the glaucoma surgery Ahmed valve implantation. Approximately 100 patients will be enrolled, with half receiving the Mitomycin-C treatment and the other half receiving placebo treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mitosol

Condition Name

Condition Name for Mitosol
Intervention Trials
Stage IIIA Bladder Cancer AJCC v8 3
Stage III Bladder Cancer AJCC v8 3
Stage II Bladder Cancer AJCC v8 2
Stage IIIB Bladder Cancer AJCC v8 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mitosol
Intervention Trials
Carcinoma 7
Carcinoma, Transitional Cell 3
Urinary Bladder Neoplasms 3
Carcinoma, Squamous Cell 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mitosol

Trials by Country

Trials by Country for Mitosol
Location Trials
United States 164
China 1
India 1
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mitosol
Location Trials
Minnesota 6
Ohio 5
Missouri 5
Kentucky 5
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mitosol

Clinical Trial Phase

Clinical Trial Phase for Mitosol
Clinical Trial Phase Trials
Phase 3 2
Phase 2 8
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mitosol
Clinical Trial Phase Trials
Recruiting 4
Completed 3
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mitosol

Sponsor Name

Sponsor Name for Mitosol
Sponsor Trials
National Cancer Institute (NCI) 9
Mayo Clinic 2
University of North Carolina 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mitosol
Sponsor Trials
Other 16
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Mallinckrodt
Baxter
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.